Business
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
GENEVA, July 07, 2025--Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
About this update from Alcon Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":202,"url":"https://media.zenfs.com/en/business-wire.com/346ef7a20d4865500de2045781faa096"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wnRGuk2vj18PUUQVZ.Revg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/346ef7a20d4865500de2045781faa096","width":480,"height":202}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2","length":204,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4","length":146,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases","length":135,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":485,"olType":false},{"type":"text","content":"GENEVA, July 07, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.1 LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.2,* Dry AMD is a progressive disease typically treated in late stage, with limited treatment options.2","length":587,"tagName":"p"},{"type":"text","content":""For more than 25 years, Alcon has been a leader in vitreoretinal surgery, and we are excited to expand our offerings into the clinic, to help millions of people living with dry AMD gain vision," said Sean Clark, Vice President and General Manager, Global Surgical Franchise, Alcon. "Dry AMD is an area of significant unmet need, and PBM is an efficacious, non-invasive light therapy that can pr...